Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

KRAS in Colorectal Cancer Therapy

  • Manfred Schwab
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7031-2

Definition

Metastatic colorectal cancer is the third most common cancer and the second most common cause of cancer-related deaths. Although the number of patients surviving 5 years with advanced-stage mCRC remains small, recent advances in personalized cancer medicine may be able to separate out those that respond to novel cytotoxic and biological agents versus those that do not respond to these agents.

Curren treatments for patients with colorectal cancer include several targeted monoclonal antibodies, as well as conventional chemotherapeutic agents. Bevacizumab (Avastin®), cetuximab (Erbitux®), and panitumumab (Vectibix™), along with conventional chemotherapeutic drugs, are some of the most commonly used agents to treat patients with mCRC.

Both cetuximab and panitumumab interact with the epidermal growth factor receptor(EGFR). These drugs fall into a category of agents called anti-EGFR therapies. Recent data now suggest a differential response to anti-EGFR antibody therapy based on...

Keywords

Colorectal Cancer Epidermal Growth Factor Receptor KRAS Mutation Good Supportive Care mCRC Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

See Also

  1. (2012) Biomarkers. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 408–409. doi: 10.1007/978-3-642-16483-5_6601Google Scholar
  2. (2012) Codon. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 891. doi: 10.1007/978-3-642-16483-5_1248Google Scholar
  3. (2012) MAPK. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2167. doi: 10.1007/978-3-642-16483-5_3532Google Scholar
  4. (2012) Mutation. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2412. doi:10.1007/978-3-642-16483-5_3911Google Scholar
  5. (2012) Panitumumab. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2779. doi:10.1007/978-3-642-16483-5_4362Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.German Cancer Research Center (DKFZ)HeidelbergGermany